Tekla Healthcare Investors (HQH)
24.00
+0.10 (+0.42%)
USD |
NYSE |
Nov 26, 12:59
24.00
0.00 (0.00%)
After-Hours: 13:59
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 1.10% | -0.58% | 1.092B | 102750.0 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.24% | 52.44% | -- | Upgrade |
Basic Info
| Investment Strategy | |
| To achieve long-term capital appreciation by investing at least 80% of its assets in securities of health services and medical technology companies. The Trust may invest up to 20% of its net assets in non-US securities and up to 40% in venture capital or other securities subject to legal or contractual restrictions as to resale. |
| General | |
| Security Type | Closed-End Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Hambrecht & Quist |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Daniel Omstead | 20.10 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-4.455B
Category Low
5.794B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
Date Unavailable
Performance Versus Category
As of November 24, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of November 24, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Moderna Inc | 5.98% | 330.54 | 20.90% |
| Amgen Inc | 5.13% | 201.33 | -1.29% |
| Gilead Sciences Inc | 5.02% | 70.48 | 0.59% |
| Illumina Inc | 4.36% | 370.23 | 1.28% |
| Vertex Pharmaceuticals Inc | 3.58% | 183.70 | -1.36% |
| Horizon Therapeutics PLC | 3.46% | 104.50 | -0.35% |
| Biogen Inc | 3.38% | 243.26 | -2.75% |
| Regeneron Pharmaceuticals Inc | 3.34% | 644.77 | -0.53% |
| State Street Instl US Govt MMkt Instl | 2.12% | 1.00 | 0.00% |
| Abbott Laboratories | 1.64% | 126.17 | 0.88% |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| To achieve long-term capital appreciation by investing at least 80% of its assets in securities of health services and medical technology companies. The Trust may invest up to 20% of its net assets in non-US securities and up to 40% in venture capital or other securities subject to legal or contractual restrictions as to resale. |
| General | |
| Security Type | Closed-End Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Hambrecht & Quist |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Daniel Omstead | 20.10 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (11-26-21) | 0.24% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 26.89 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of June 30, 2021
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 4/23/1987 |
| Last Annual Report Date | 9/30/2020 |
| Last Prospectus Date | 2/7/1997 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan |
|
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)